Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

Weren't you under the impression that B-ABSSSI's ability to overcome the antibiotic resistance issue was its primary source of differentiation?

At equal cost? Yes.

Against a much cheaper generic that still works? Apparently not or we would have done a deal.

unmet need issue that resulted from high competition

I don't think there is a large unmet need for ABSSSI at this time. Big pharma and insurance companies are doing the math and taking the patient out of the equation. The existing batch of generics seem to be doing pretty well. Maybe in 10 years that will change but for the useful life of B-ABSSSI it seems it would be playing backup QB.

Go IPIX!